These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27406953)

  • 1. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
    Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
    J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
    Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
    Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1
    Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
    Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T2 mapping of molecular subtypes of WHO grade II/III gliomas.
    Kern M; Auer TA; Picht T; Misch M; Wiener E
    BMC Neurol; 2020 Jan; 20(1):8. PubMed ID: 31914945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With
    Bruno F; Pellerino A; Conti Nibali M; Pronello E; Cofano F; Rossi M; Levis M; Bertero L; Soffietti R; Cassoni P; Garbossa D; Bello L; Rudà R
    Neurology; 2024 May; 102(10):e209352. PubMed ID: 38684041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.
    Rice T; Zheng S; Decker PA; Walsh KM; Bracci P; Xiao Y; McCoy LS; Smirnov I; Patoka JS; Hansen HM; Hsuang G; Wiemels JL; Tihan T; Pico AR; Prados MD; Chang SM; Berger MS; Caron A; Fink S; Kollmeyer T; Rynearson A; Voss J; Kosel ML; Fridley BL; Lachance DH; Eckel-Passow JE; Sicotte H; O'Neill BP; Giannini C; Wiencke JK; Jenkins RB; Wrensch MR
    Neuro Oncol; 2013 May; 15(5):535-41. PubMed ID: 23361564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Immunohistochemical Expression of ALK-1 in Gliomas, WHO Grade 4 and Its Correlation with IDH1-R132H Mutation Status.
    Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant IDH1 and thrombosis in gliomas.
    Unruh D; Schwarze SR; Khoury L; Thomas C; Wu M; Chen L; Chen R; Liu Y; Schwartz MA; Amidei C; Kumthekar P; Benjamin CG; Song K; Dawson C; Rispoli JM; Fatterpekar G; Golfinos JG; Kondziolka D; Karajannis M; Pacione D; Zagzag D; McIntyre T; Snuderl M; Horbinski C
    Acta Neuropathol; 2016 Dec; 132(6):917-930. PubMed ID: 27664011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and outcomes of IDH1-mutant gliomas in elderly patients.
    Giantini-Larsen AM; Abou-Mrad Z; Yu KK; Reiner AS; Bale TA; Tabar V; Bander ED
    J Neurosurg; 2024 Feb; 140(2):367-376. PubMed ID: 37877960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH1 mutation predicts seizure occurrence and prognosis in lower-grade glioma adults.
    Tang T; Wang Y; Dai Y; Liu Q; Fan X; Cheng Y; Tang J; Xiao X; Shan Y; Wei P; Zhao G
    Pathol Res Pract; 2024 Feb; 254():155165. PubMed ID: 38286053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
    Capper D; Weissert S; Balss J; Habel A; Meyer J; Jäger D; Ackermann U; Tessmer C; Korshunov A; Zentgraf H; Hartmann C; von Deimling A
    Brain Pathol; 2010 Jan; 20(1):245-54. PubMed ID: 19903171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data.
    Kim N; Kim SH; Kang SG; Moon JH; Cho J; Suh CO; In Yoon H; Chang JH
    Radiat Oncol; 2020 Jul; 15(1):184. PubMed ID: 32736562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas.
    Arita H; Kinoshita M; Kawaguchi A; Takahashi M; Narita Y; Terakawa Y; Tsuyuguchi N; Okita Y; Nonaka M; Moriuchi S; Takagaki M; Fujimoto Y; Fukai J; Izumoto S; Ishibashi K; Nakajima Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Mori K; Ichimura K; Kanemura Y
    Sci Rep; 2018 Aug; 8(1):11773. PubMed ID: 30082856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma.
    Iwahashi H; Nagashima H; Tanaka K; Uno T; Hashiguchi M; Maeyama M; Somiya Y; Komatsu M; Hirose T; Itoh T; Sasaki R; Sasayama T
    J Neurosurg; 2023 Aug; 139(2):355-362. PubMed ID: 36708540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep learning-based IDH1 gene mutation prediction using histopathological imaging and clinical data.
    Nakagaki R; Debsarkar SS; Kawanaka H; Aronow BJ; Prasath VBS
    Comput Biol Med; 2024 Sep; 179():108902. PubMed ID: 39038392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.
    Drumm MR; Wang W; Sears TK; Bell-Burdett K; Javier R; Cotton KY; Webb B; Byrne K; Unruh D; Thirunavu V; Walshon J; Steffens A; McCortney K; Lukas RV; Phillips JJ; Mohamed E; Finan JD; Santana-Santos L; Heimberger AB; Franz CK; Kurz J; Templer JW; Swanson GT; Horbinski C
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37104042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
    Andronesi OC; Kim GS; Gerstner E; Batchelor T; Tzika AA; Fantin VR; Vander Heiden MG; Sorensen AG
    Sci Transl Med; 2012 Jan; 4(116):116ra4. PubMed ID: 22238332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epilepsy in gliomas: recent insights into risk factors and molecular pathways.
    Rudà R; Bruno F; Pellerino A
    Curr Opin Neurol; 2023 Dec; 36(6):557-563. PubMed ID: 37865836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation Over Time.
    Voisin MR; Gui C; Patil V; Gao AF; Zadeh G
    Can J Neurol Sci; 2024 May; 51(3):362-368. PubMed ID: 37434550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis.
    Sporikova Z; Slavkovsky R; Tuckova L; Kalita O; Megova Houdova M; Ehrmann J; Hajduch M; Hrabalek L; Vaverka M
    Appl Immunohistochem Mol Morphol; 2022 Mar; 30(3):178-183. PubMed ID: 35262523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.